Category: by subject

Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

Elizabeth Moylan
Rachel Burley

Over the decades, the concept of peer review has changed dramatically – so what does the future hold? That’s a question examined in a new report issued today by BioMed Central and Digital Science, based on discussions held during the SpotOn London conference. (Disclosure: Our co-founder Ivan Oransky spoke there.) We spoke with Elizabeth Moylan, Senior Editor Research Integrity at BioMed Central, and Rachel Burley, Publishing Director at BioMed Central about the central question posed by the report: What will peer review look like in the year 2030?

Retraction Watch: People have many complaints about peer review. What do you think are its most pressing flaws?

Continue reading Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

“Remarkable” it was ever accepted, says report: Science to retract study on fish and microplastics

Science is retracting a paper about how human pollution is harming fish, after months of questions about the validity of the data.

The move, first reported by the news side of Science on Friday, follows a new report from a review board in Sweden that concluded the authors were guilty of “scientific dishonesty,” and the paper should be “recalled.”

The report had some strong words for the journal and the university that conducted a preliminary investigation:

Continue reading “Remarkable” it was ever accepted, says report: Science to retract study on fish and microplastics

University suggests journal correct diabetes paper. Publisher retracts it.

After a publisher learned there may be issues with a 2008 diabetes paper, it asked the author’s university to investigate. The university found evidence of image duplication, and asked the journal to consider correcting the paper.

Instead, the journal has retracted it.

The backstory involves diabetes researcher Kathrin Maedler, who has one previous retraction, as well as multiple corrections. Even the paper in question, published in Diabetes, received an erratum in 2014 regarding a duplicated image, as well as an expression of concern last August after the American Diabetes Association questioned “the reliability of the data” in both the article and erratum.

According to the expression of concern, the ADA asked the University of Bremen to investigate the issues in the paper. In October, the University of Bremen concluded that several duplications present in her work were the result of negligence, not misconduct.

To resolve the issues, the university’s rector recommended that the authors publish a second erratum with corrected figures. But after conducting its own review, the ADA overruled the university, opting instead to retract the paper:

Continue reading University suggests journal correct diabetes paper. Publisher retracts it.

Former rising star found guilty of misconduct issues 2nd retraction

A once-lauded researcher in the field of infectious disease — who has since been found guilty of misconduct — has retracted a second paper.

Last year, the University of Dundee in Scotland investigated and ultimately concluded that Robert Ryan — whose work focused on infections that can be deadly in people with lung diseases such as cystic fibrosis — had committed “serious research misconduct,” affecting multiple publications. After appealing the decision, Ryan resigned.

We covered his first retraction earlier this month, which cited multiple instances of image duplication. Now Ryan has retracted his second paper, published in 2011 in Journal of Bacteriology, also due to image problems.

Here’s the retraction notice: Continue reading Former rising star found guilty of misconduct issues 2nd retraction

Harvard teaching hospital to pay $10 million to settle research misconduct allegations

Piero Anversa

Brigham and Women’s Hospital and its parent healthcare network have agreed to pay $10 million to the U.S. government to resolve allegations it fraudulently obtained federal funding.

The case, which involves three former Harvard stem cell researchers, dates back several years. In 2014, Circulation retracted a paper by Piero Anversa, Annarosa Leri, and Jan Kajstura, among others, amidst a university investigation into misconduct allegations. Anversa and Leri — whose lab was described as filled with “fear” by one former research fellow — later sued the hospital for notifying journals of that investigation. They lost.

In the agreement announced today by the Department of Justice (DOJ), Partners Healthcare and Brigham and Women’s Hospital have agreed to pay the government $10 million to settle allegations that the researchers fraudulently obtained funding from the National Institutes of Health:

Continue reading Harvard teaching hospital to pay $10 million to settle research misconduct allegations

Public health journal’s editorial board tells publisher they have “grave concerns” over new editor

First, an occupational health journal appointed a new editor with industry ties without consulting the editorial board. Then, with no explanation, it withdrew a paper by the previous editor that was critical of corporate-sponsored research — again, without consulting the editorial board.

At that point, they’d had enough.

Yesterday, the editorial board of the International Journal of Occupational and Environmental Health sent a letter to the publisher, Taylor & Francis, expressing their “grave concerns” over the future of the journal, and its recent actions.

As part of the letter — signed by 30 past and present editorial members and the founding editor — they write:

Continue reading Public health journal’s editorial board tells publisher they have “grave concerns” over new editor

A university asked for numerous retractions. Eight months later, three journals have done nothing.

Anil Jaiswal

When journals learn papers are problematic, how long does it take them to act?

We recently had a chance to find out as part of our continuing coverage of the case of Anil Jaiswal at the University of Maryland, who’s retracted 15 papers (including two new ones we recently identified), and has transitioned out of cancer research. Here’s what happened.

As part of a public records request related to the investigation, we received letters that the University of Maryland sent to 11 journals regarding 26 “compromised” papers co-authored by Jaiswal, four of which had been retracted by the time of the letter. The letters were dated between August and September 2016 (and one in February) — although, in some cases, the journals told us they received the letter later. Since that date, three journals have retracted nine papers and corrected another, waiting between four and six months to take action. One journal published an editorial note of concern within approximately two months after the university letter.

And six journals have not taken any public action.

Continue reading A university asked for numerous retractions. Eight months later, three journals have done nothing.

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Continue reading A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Harvard diabetes researcher retracts third paper

A prominent diabetes researcher based at Harvard Medical School has retracted a third paper, citing manipulation of multiple figures.

Late last year, Carl Ronald Kahn—also chief academic officer at Joslin Diabetes Center—retracted two papers for similar reasons. In November, Kahn pulled a 2005 paper from The Journal of Clinical Investigation (JCI) and a month later, he retracted a 2003 paper from The Journal of Biological Chemistry (JBC), both times citing duplications that the authors said were introduced while assembling the figures.

Last month, Kahn retracted his third paper, also published in JBC in 2003, because the authors omitted data when constructing the images. Still, the authors remain confident in their findings, given that data from other labs “have confirmed and extended the conclusions of the manuscript.”

Here’s the retraction notice: Continue reading Harvard diabetes researcher retracts third paper

Plant biologist earns string of retractions, bringing total to 9

A pair of plant biologists has lost a string of papers over concerns about image manipulation. One author has added eight new retractions to his CV; the other has added five.

Last summer, a journal retracted another paper by the pair, also citing suspicions of image manipulation. The latest batch of retractions — issued by seven different journals — includes some papers that have been questioned on PubPeer.

Dibyendu Talukdar, listed at the University of Calcutta in West Bengal, India, is the sole author on three retracted papers. He shares five new retractions with Tulika Talukdar listed at the University of North Bengal. That brings their totals to nine and six, respectively. (We’re not sure if the Drs. Talukdar are related).

We’ll start with the papers they share: Continue reading Plant biologist earns string of retractions, bringing total to 9